How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?

Pediatric Infectious Disease Journal

Volumn 25, Issue 3, 2006, Pages 195-200

  Halperin, Scott A ^a   Sweet, Lamont ^b   Baxendale, Darlene ^a   Neatby, Anne ^b   Rykers, Petra ^a   Smith, Bruce ^a   Zelman, Mitchell ^b   Maus, Diane ^d   Lavigne, Pierre ^c   Decker, Michael D ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Department of Health and Social Services ^*  (Canada)

^c Sanofi Pasteur   (Canada)

^d SANOFI PASTEUR   (France)

Author keywords

Adult formulation tetanus and diphtheria toxoids and acellular pertussis vaccines; Booster dose; Pertussis vaccine

Indexed keywords

ADACEL; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE;

ADOLESCENT; ARTHUS PHENOMENON; ARTICLE; ASTHMA; BRONCHOSPASM; CHILD; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; JUVENILE DIABETES MELLITUS; LIMB SWELLING; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; SYNCOPE;

ADULT; CHEMISTRY, PHARMACEUTICAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA; DIPHTHERIA-TETANUS VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; TETANUS; TIME FACTORS; VACCINATION; WHOOPING COUGH;

EID: 33644930050     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000202082.56403.c4     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR. 2002;51:73-76.
2. Andrews R, Herceg A, Roberts C. Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell. 1997;21:145-148.
3. Public Health Agency of Canada. Vaccine-preventable diseases: Pertussis. Available at: http://www.phac-aspc.gc.ca/dird-dimr/vpd-mev/pertussis_e.html. Accessed April 8, 2005.
4. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: Thirty years after a routine use of vaccination. Pediatr Infect Dis J. 1998;17:412-418.
5. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med. 1996;150:457-460.
6. Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S, for members of the Canadian Paediatric Society/Health Canada Immunization Monitoring Program-Active (IMPACT). Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics. 2003;112:e348-e853.
7. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS, and the VAERS Working Group. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics. 2000;106:e51.
8. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-1237.
9. Gilberg S, Njamkepo E, Du Chatelet IP, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis. 2002;186:415-418.
10. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada [published correction appears in J Infect Dis. 2002;185:1696]. J Infect Dis. 2002;185:1448-1453.
11. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis. 2000;182:1409-1416.
12. Schmitt-Grohé S, Cherry JD, Heininger U, Uberall MA, Pineda E, Stehr K. Pertussis in German adults. Clin Infect Dis. 1995;21:860-866.
13. Jenkinson D. Duration of effectiveness of pertussis vaccine: Evidence from a 10-year community study. Br Med J. 1988;296:612-614.
14. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep. 1965;80:365-369.
15. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: The Italian experience. Paediatrics. 2001;108:e81.
16. Halperin SA. Pertussis immunization for adolescents: What are we waiting for? Paediatr Child Health. 2001;6:184-186.
17. National Advisory Committee on Immunization (NACI). Prevention of pertussis in adolescents and adults. Can Commun Dis Rep. 2003;29:1-9.
18. Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000;18:1312-1319.
19. Halperin SA, Smith B, Russell M, et al. Adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J. 2000;19:276-283.
20. Peebles TC, Levine L, Eldred ML, Edsall G. Tetanus-toxoid emergency boosters: A reappraisal. N Engl J Med. 1969;280:575-581.
21. Edsall G, Elliot MW, Peebles TC, Levine L, Eldred MC. Excessive use of tetanus toxoid boosters. JAMA. 1967;202:17-19.
22. Levine L, Edsall G. Tetanus toxoid: What determines reaction proneness? J Infect Dis. 1981;144:376.
23. Campins-Martí M, Cheng HK, Forsyth K, et al. International Consensus Group on Pertussis Immunisation. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine. 2001;20:641-646.
24. Wirsing von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002;2:744-750.
25. Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine. 1998;16:1016-1023.
26. Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000;105:e12.
27. Skowronski DM, Remple VP, Macnabb J, et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics. 2003;112:e453-e459.
28. Halperin SA, Scheifele D, Mills E, et al. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine. 2003;21:2298-2306.
29. Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine. 2001;19:4720-4726.
30. Centers for Disease Control and Prevention. Update on adult immunization recommendations of the immunization practices advisory committee (ACIP). MMWR. 1991;40:1-52.
31. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin Infect Dis. 2004;39:1802-1809.
32. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: Computer simulations of five new strategies. Vaccine. 2004;22:3154-3165.